The immunological challenges of cell transplantation for the treatment of Parkinson's disease

Amanda L. Piquet, Kala Venkiteswaran, Neena I. Marupudi, Matthew Berk, Thyagarajan Subramanian

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

Dopaminergic cell transplantation is an experimental therapy for Parkinson's disease (PD). It has many potential theoretical advantages over current treatment strategies such as providing continuous local dopaminergic replenishment, eliminating motor fluctuations and medication-induced dyskinesias, slowing down disease progression or even reversing disease pathology in the host. Recent studies also show that dopaminergic cell transplants provide long-term neuromodulation in the basal ganglia that simulates the combined effects of oral dopaminergic therapy and surgical therapies like deep brain stimulation, the contemporary therapeutic approach to advanced PD. However, dopaminergic cell transplantation in PD as not been optimized and current experimental techniques have many drawbacks. In published experiments to date of attempted dopaminergic grafting in PD, the major challenges are unacceptable graft-induced dyskinesias or failure of such grafts to exceed the benefits afforded by sham surgery. A deleterious host immune response to the transplant has been implicated as a major putative cause for these adverse outcomes. This article focuses on recent advances in understanding the immunology of the transplantation in PD and possible methods to overcome adverse events such that we could translate cell replacement strategies into viable clinical treatments in the future.

Original languageEnglish (US)
Pages (from-to)320-331
Number of pages12
JournalBrain Research Bulletin
Volume88
Issue number4
DOIs
StatePublished - Jul 1 2012

Fingerprint

Cell Transplantation
Parkinson Disease
Transplants
Drug-Induced Dyskinesia
Transplantation Immunology
Therapeutics
Investigational Therapies
Deep Brain Stimulation
Dyskinesias
Parkinsonian Disorders
Basal Ganglia
Disease Progression
Pathology

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)

Cite this

@article{a4446f81c0084c729dbc5090226f9a08,
title = "The immunological challenges of cell transplantation for the treatment of Parkinson's disease",
abstract = "Dopaminergic cell transplantation is an experimental therapy for Parkinson's disease (PD). It has many potential theoretical advantages over current treatment strategies such as providing continuous local dopaminergic replenishment, eliminating motor fluctuations and medication-induced dyskinesias, slowing down disease progression or even reversing disease pathology in the host. Recent studies also show that dopaminergic cell transplants provide long-term neuromodulation in the basal ganglia that simulates the combined effects of oral dopaminergic therapy and surgical therapies like deep brain stimulation, the contemporary therapeutic approach to advanced PD. However, dopaminergic cell transplantation in PD as not been optimized and current experimental techniques have many drawbacks. In published experiments to date of attempted dopaminergic grafting in PD, the major challenges are unacceptable graft-induced dyskinesias or failure of such grafts to exceed the benefits afforded by sham surgery. A deleterious host immune response to the transplant has been implicated as a major putative cause for these adverse outcomes. This article focuses on recent advances in understanding the immunology of the transplantation in PD and possible methods to overcome adverse events such that we could translate cell replacement strategies into viable clinical treatments in the future.",
author = "Piquet, {Amanda L.} and Kala Venkiteswaran and Marupudi, {Neena I.} and Matthew Berk and Thyagarajan Subramanian",
year = "2012",
month = "7",
day = "1",
doi = "10.1016/j.brainresbull.2012.03.001",
language = "English (US)",
volume = "88",
pages = "320--331",
journal = "Brain Research Bulletin",
issn = "0361-9230",
publisher = "Elsevier Inc.",
number = "4",

}

The immunological challenges of cell transplantation for the treatment of Parkinson's disease. / Piquet, Amanda L.; Venkiteswaran, Kala; Marupudi, Neena I.; Berk, Matthew; Subramanian, Thyagarajan.

In: Brain Research Bulletin, Vol. 88, No. 4, 01.07.2012, p. 320-331.

Research output: Contribution to journalReview article

TY - JOUR

T1 - The immunological challenges of cell transplantation for the treatment of Parkinson's disease

AU - Piquet, Amanda L.

AU - Venkiteswaran, Kala

AU - Marupudi, Neena I.

AU - Berk, Matthew

AU - Subramanian, Thyagarajan

PY - 2012/7/1

Y1 - 2012/7/1

N2 - Dopaminergic cell transplantation is an experimental therapy for Parkinson's disease (PD). It has many potential theoretical advantages over current treatment strategies such as providing continuous local dopaminergic replenishment, eliminating motor fluctuations and medication-induced dyskinesias, slowing down disease progression or even reversing disease pathology in the host. Recent studies also show that dopaminergic cell transplants provide long-term neuromodulation in the basal ganglia that simulates the combined effects of oral dopaminergic therapy and surgical therapies like deep brain stimulation, the contemporary therapeutic approach to advanced PD. However, dopaminergic cell transplantation in PD as not been optimized and current experimental techniques have many drawbacks. In published experiments to date of attempted dopaminergic grafting in PD, the major challenges are unacceptable graft-induced dyskinesias or failure of such grafts to exceed the benefits afforded by sham surgery. A deleterious host immune response to the transplant has been implicated as a major putative cause for these adverse outcomes. This article focuses on recent advances in understanding the immunology of the transplantation in PD and possible methods to overcome adverse events such that we could translate cell replacement strategies into viable clinical treatments in the future.

AB - Dopaminergic cell transplantation is an experimental therapy for Parkinson's disease (PD). It has many potential theoretical advantages over current treatment strategies such as providing continuous local dopaminergic replenishment, eliminating motor fluctuations and medication-induced dyskinesias, slowing down disease progression or even reversing disease pathology in the host. Recent studies also show that dopaminergic cell transplants provide long-term neuromodulation in the basal ganglia that simulates the combined effects of oral dopaminergic therapy and surgical therapies like deep brain stimulation, the contemporary therapeutic approach to advanced PD. However, dopaminergic cell transplantation in PD as not been optimized and current experimental techniques have many drawbacks. In published experiments to date of attempted dopaminergic grafting in PD, the major challenges are unacceptable graft-induced dyskinesias or failure of such grafts to exceed the benefits afforded by sham surgery. A deleterious host immune response to the transplant has been implicated as a major putative cause for these adverse outcomes. This article focuses on recent advances in understanding the immunology of the transplantation in PD and possible methods to overcome adverse events such that we could translate cell replacement strategies into viable clinical treatments in the future.

UR - http://www.scopus.com/inward/record.url?scp=84862192349&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862192349&partnerID=8YFLogxK

U2 - 10.1016/j.brainresbull.2012.03.001

DO - 10.1016/j.brainresbull.2012.03.001

M3 - Review article

C2 - 22521427

AN - SCOPUS:84862192349

VL - 88

SP - 320

EP - 331

JO - Brain Research Bulletin

JF - Brain Research Bulletin

SN - 0361-9230

IS - 4

ER -